Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alomfilimab - Kymab/Sanofi

Next Previous
Drug Profile

Alomfilimab - Kymab/Sanofi

Alternative Names: KY-1044; SAR-445256

Latest Information Update: 01 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Inducible T-cell co-stimulator protein agonists; Regulatory T-lymphocyte inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 03 Oct 2024 Sanofi terminates a phase-II clinical trials in Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in USA, United Kingdom, Italy, Hungary, Poland and Taiwan (IV) (NCT03829501) (EudraCT2018-003172-12)
  • 23 Feb 2024 Discontinued - Phase-II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA, United Kingdom, Italy, Taiwan, Hungary, Poland (IV) prior to February 2024
  • 23 Feb 2024 Discontinued - Phase-II for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA, United Kingdom, Taiwan, Italy, Hungary, Poland (IV) prior to February 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top